Targeting acute myeloid leukemia cells with cytokines

Journal of Leukocyte Biology

Volumn 92, Issue 3, 2012, Pages 567-575

  Ferretti, Elisa ^a   Cocco, Claudia ^a   Airoldi, Irma ^a   Pistoia, Vito ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTOKINE; FLUDARABINE PHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 27; INTERLEUKIN 3;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; DRUG CYTOTOXICITY; DRUG SPECIFICITY; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZED CHILD; HUMAN; IMMUNOMODULATION; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TARGET CELL DESTRUCTION; TUMOR CLASSIFICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS;

EID: 84865458752     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0112036     Document Type: Review

References (99)

1. Carroll, W. L., Bhojwani, D., Min, D. J., Raetz, E., Relling, M., Davies, S., Downing, J. R., Willman, C. L., Reed, J. C. (2003) Pediatric acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program, 102
2. Stone, R. M., O'Donnell, M. R., Sekeres, M. A. (2004) Acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program, 98-117.
3. Kaspers, G. J., Zwaan, C. M. (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 92, 1519-1532.
4. Pui, C. H., Carroll, W. L., Meshinchi, S., Arceci, R. J. (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29, 551-565.
5. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R., Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51, 189-199.
6. Bacher, U., Kern, W., Schnittger, S., Hiddemann, W., Schoch, C., Hafer-lach, T. (2005) Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann. Hematol. 84, 785-791.
7. Balgobind, B. V., Zwaan, C. M., Pieters, R., Van den Heuvel-Eibrink, M. M. (2011) The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 25, 1239-1248.
8. Balgobind, B. V., Raimondi, S. C., Harbott, J., Zimmermann, M., Alonzo, T. A., Auvrignon, A., Beverloo, H. B., Chang, M., Creutzig, U., Dworzak, M. N., Forestier, E., Gibson, B., Hasle, H., Harrison, C. J., Heerema, N. A., Kaspers, G. J., Leszl, A., Litvinko, N., Nigro, L. L., Mo-rimoto, A., Perot, C., Pieters, R., Reinhardt, D., Rubnitz, J. E., Smith, F. O., Stary, J., Stasevich, I., Strehl, S., Taga, T., Tomizawa, D., Webb, D., Zemanova, Z., Zwaan, C. M., van den Heuvel-Eibrink, M. M. (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114, 2489-2496.
9. Dick, J. E. (2009) Looking ahead in cancer stem cell research. Nat. Bio-technol. 27, 44-46.
10. Bonnet, D., Dick, J. E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.
11. Hope, K J., Jin, L., Dick, J. E. (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738-743.
12. Buss, E. C., Ho, A. D. (2011) Leukemia stem cells. Int. J. Cancer 129, 2328-2336.
13. Adams, J. M., Strasser, A. (2008) Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 68, 4018-4021.
14. Gupta, P. B., Chaffer, C. L., Weinberg, R. A. (2009) Cancer stem cells: mirage or reality? Nat. Med. 15, 1010-1012.
15. Dick, J. E., Lapidot, T. (2005) Biology of normal and acute myeloid leukemia stem cells. Int. J. Hematol. 82, 389-396.
16. Lane, S. W., Scadden, D. T., Gilliland, D. G. (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114, 1150-1157.
17. Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., Nakamura, R., Tanaka, T., Tomiyama, H., Saito, N., Fukata, M., Miyamoto, T., Lyons, B., Ohshima, K, Uchida, N., Taniguchi, S., Ohara, O., Akashi, K, Harada, M., Shultz, L. D. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25, 1315-1321.
18. Colmone, A., Amorim, M., Pontier, A. L., Wang, S., Jablonski, E., Sip-kins, D. A. (2008) Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322, 1861-1865.
19. Karp, J. E., Gojo, I., Pili, R., Gocke, C. D., Greer, J., Guo, C., Qian, D., Morris, L., Tidwell, M., Chen, H., Zwiebel, J. (2004) Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential ι-β-D-arabinofuranosylcyto-sine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 10, 3577-3585.
20. Konopleva, M. Y., Jordan, C. T. (2011) Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 29, 591-599.
21. Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs K D., Jr., van Rooijen, N., Weissman, I. L. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299.
22. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., Dick, J. E. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648.
23. Mansson, R., Hultquist, A., Luc, S., Yang, L., Anderson, K, Kharazi, S., Al-Hashmi, S., Liuba, K, Thoren, L., Adolfsson, J., Buza-Vidas, N., Qian, H., Soneji, S., Enver, T., Sigvardsson, M., Jacobsen, S. E. (2007) Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 26, 407-419.
24. Taussig, D. C., Miraki-Moud, F., Anjos-Afonso, F., Pearce, D. J., Allen, K, Ridler, C., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., Lister, T. A., Gribben, J. G., Bonnet, D. (2008) Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112, 568-575.
25. Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F., Dick, J. E. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167-1174.
26. Jin, L., Lee, E. M., Ramshaw, H. S., Busfield, S. J., Peoppl, A. G., Wilkinson, L., Guthridge, M. A., Thomas, D., Barry, E. F., Boyd, A., Gearing, D. P., Vairo, G., Lopez, A. F., Dick, J. E., Lock, R. B. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor a chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5, 31-42.
27. Sarry, J. E., Murphy, K, Perry, R., Sanchez, P. V., Secreto, A., Keefer, C., Swider, C. R., Strzelecki, A. C., Cavelier, C., Recher, C., Mansat-De Mas, V., Delabesse, E., Danet-Desnoyers, G., Carroll, M. (2011) Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Ryc-deficient mice. J. Clin. Invest. 121, 384395.
28. Zhou, B. B., Zhang, H., Damelin, M., Geles, K G., Grindley, J. C., Dirks, P. B. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8, 806-823.
29. Tallman, M. S., Gilliland, D. G., Rowe, J. M. (2005) Drug therapy for acute myeloid leukemia. Blood 106, 1154-1163.
30. Kolitz, J. E. (2006) Current therapeutic strategies for acute myeloid leukaemia. Br. J. Haematol. 134, 555-572.
31. Van Rhenen, A., Feller, N., Kelder, A., Westra, A. H., Rombouts, E., Zweegman, S., van der Pol, M. A., Waisfisz, Q., Ossenkoppele, G. J., Schuurhuis, G. J. (2005) High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11, 6520-6527.
32. Strahm, B., Nollke, P., Zecca, M., Korthof, E. T., Bierings, M., Furlan, I., Sedlacek, P., Chybicka, A., Schmugge, M., Bordon, V., Peters, C., O'Marcaigh, A., de Heredia, C. D., Bergstraesser, E., Moerloose, B. D., van den Heuvel-Eibrink, M. M., Stary, J., Trebo, M., Wojcik, D., Ni-emeyer, C. M., Locatelli, F. (2011) Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 25, 455-462.
33. Gesundheit, B., Shapira, M. Y., Resnick, I. B., Amar, A., Kristt, D., Dray, L., Budowski, E., Or, R. (2009) Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation. Am. J. Hematol. 84, 188-190.
34. Styczynski, J. (2007) Drug resistance in childhood acute myeloid leukemia. Curr. Pharm. Biotechnol. 8, 59-75.
35. Rubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., Taub, J., Pounds, S., Razzouk, B. I., Lacayo, N.J., Cao, X., Meshinchi, S., De-gar, B., Airewele, G., Raimondi, S. C., Onciu, M., Coustan-Smith, E., Downing, J. R., Leung, W., Pui, C. H., Campana, D. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 11, 543-552.
36. Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., Caligiuri, M. A. (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100, 1935-1947.
37. Ljunggren, H. G., Malmberg, K J. (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329339.
38. Velardi, A., Ruggeri, L., Mancusi, A., Aversa, F., Christiansen, F. T. (2009) Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr. Opin. Immunol. 21, 525-530.
39. Moretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M. C., Moretta, A. (2011) Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117, 764-771.
40. Brune, M., Castaigne, S., Catalano, J., Gehlsen, K., Ho, A. D., Hofmann, W. K., Hogge, D. E., Nilsson, B., Or, R., Romero, A. I., Rowe, J. M., Si-monsson, B., Spearing, R., Stadtmauer, E. A., Szer, J., Wallhult, E., Hell-strand, K. (2006) Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 108, 88-96.
41. Oshimi, K., Oshimi, Y., Akutsu, M., Takei, Y., Saito, H., Okada, M., Mizoguchi, H. (1986) Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68, 938-948.
42. Goodman, M., Cabral, L., Cassileth, P. (1998) Interleukin-2 and leukemia. Leukemia 12, 1671-1675.
43. Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, S., Tos, A. G., Mandelli, F. (1994) Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84, 2158-2163.
44. Ravandi, F. (2006) Role of cytokines in the treatment of acute leuke-mias: a review. Leukemia 20, 563-571.
45. Margolin, K., Forman, S. J. (2000) Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy. Cancer J. Sci. Am. 6 (Suppl. 1), S33-S38.
46. Foa, R., Meloni, G., Tosti, S., Novarino, A., Fenu, S., Gavosto, F., Man-delli, F. (1991) Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Br. J. Haematol. 77, 491-496.
47. Maraninchi, D., Vey, N., Viens, P., Stoppa, A. M., Archimbaud, E., Attal, M., Baume, D., Bouabdallah, R., Demeoq, F., Fleury, J., Michallet, M., Olive, D., Reiffers, J., Sainty, D., Tabilio, A., Tiberghien, P., Brandely, M., Hercend, T., Blaise, D. (1998) A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk. Lymphoma 31, 343-349.
48. Baer, M. R., George, S. L., Caligiuri, M. A., Sanford, B. L., Bothun, S. M., Mrozek, K., Kolitz, J. E., Powell, B. L., Moore, J. O., Stone, R. M., Anastasi, J., Bloomfield, C. D., Larson, R. A. (2008) Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J. Clin. Oncol. 26, 49344939.
49. Meloni, G., Foa, R., Capria, S., Tosti, S., Vignetti, M., Gavosto, F., Man-delli, F. (1992) IL-2 for the treatment of acute leukemias. Leukemia 6 (Suppl. 2), 28-30.
50. Lange, B. J., Smith, F. O., Feusner, J., Barnard, D. R., Dinndorf, P., Feig, S., Heerema, N. A., Arndt, C., Arceci, R. J., Seibel, N., Weiman, M., Dusenbery, K, Shannon, K, Luna-Fineman, S., Gerbing, R. B., Alonzo, T. A. (2008) Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 111, 1044-1053.
51. Vitale, A., Guarini, A., Latagliata, R., Cignetti, A., Foa, R. (1998) Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts. Br. J. Haematol. 101, 150
52. Roychowdhury, S., May K F., Jr., Tzou, K S., Lin, T., Bhatt, D., Freud, A. G., Guimond, M., Ferketich, A. K., Liu, Y., Caligiuri, M. A. (2004) Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res. 64, 8062-8067.
53. Foley, B., Cooley, S., Verneris, M. R., Curtsinger, J., Luo, X., Waller, E. K., Weisdorf, D. J., Miller, J. S. (2011) NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 118, 2784-2792.
54. Jordan, C. T., Upchurch, D., Szilvassy, S. J., Guzman, M. L., Howard, D. S., Pettigrew, A. L., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D. A., Luger, S. M., Phillips, G. L. (2000) The interleukin-3 receptor a chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777-1784.
55. Munoz, L., Nomdedeu, J. F., Lopez, O., Carnicer, M. J., Bellido, M., Aventin, A., Brunet, S., Sierra, J. (2001) Interleukin-3 receptor a chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86, 1261-1269.
56. Cannistra, S. A., Groshek, P., Griffin, J. D. (1989) Granulocyte-macro-phage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 3, 328-334.
57. Bhalla, K, Holladay, C., Arlin, Z., Grant, S., Ibrado, A. M., Jasiok, M. (1991) Treatment with interleukin-3 plus granulocyte-macrophage colo ny-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood 78, 2674-2679.
58. Lowenberg, B., van Putten, W., Theobald, M., Gmur, J., Verdonck, L., Sonneveld, P., Fey, M., Schouten, H., de Greef, G., Ferrant, A., Kovacso-vics, T., Gratwohl, A., Daenen, S., Huijgens, P., Boogaerts, M. (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N. Engl. J. Med. 349, 743-752.
59. Agliano, A., Martin-Padura, I., Mancuso, P., Marighetti, P., Rabascio, C., Pruneri, G., Shultz, L. D., Bertolini, F. (2008) Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Ry null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int. J. Cancer 123, 2222-2227.
60. Ishikawa, F., Yasukawa, M., Lyons, B., Yoshida, S., Miyamoto, T., Yo-shimoto, G., Watanabe, T., Akashi, K, Shultz, L. D., Harada, M. (2005) Development of functional human blood and immune systems in NOD/ SCID/IL2 receptor {7} chain(null) mice. Blood 106, 1565-1573.
61. Morisot, S., Wayne, A. S., Bohana-Kashtan, O., Kaplan, I. M., Gocke, C. D., Hildreth, R., Stetler-Stevenson, M., Walker, R. L., Davis, S., Melt-zer, P. S., Wheelan, S. J., Brown, P., Jones, R. J., Shultz, L. D., Civin, C. I. (2010) High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia 24,
62. Ferretti, E., Montagna, D., Di Carlo, E., Cocco, C., Ribatti, D., Ognio, E., Sorrentino, C., Lisini, D., Bertaina, A., Locatelli, F., Pistoia, V., Airoldi, I. (2012) Absence of IL-12R^2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R7C-defi-cient mice. Leukemia 26, 225-235.
63. Zorzoli, A., Di Carlo, E., Cocco, C., Ognio, E., Ribatti, D., Ferretti, E., Dufour, C., Locatelli, F., Montagna, D., Airoldi, I. (2012) Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/ Il2rg-/-mice. Clin. Cancer Res. 18, 1630-1640.
64. Hunter, C. A. (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531.
65. Trinchieri, G., Pflanz, S., Kastelein, R. A. (2003) The IL-12 family of het-erodimeric cytokines: new players in the regulation of T cell responses. Immunity 19, 641-644.
66. Colombo, M. P., Trinchieri, G. (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 155-168.
67. Chua, A. O., Chizzonite, R., Desai, B. B., Truitt, T. P., Nunes, P., Mi-netti, L. J., Warrier, R. R., Presky, D. H., Levine, J. F., Gately, M. K. (1994) Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J. Immunol. 153, 128-136.
68. Presky, D. H., Yang, H., Minetti, L. J., Chua, A. O., Nabavi, N., Wu, C. Y., Gately, M. K, Gubler, U. (1996) A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA 93, 14002-14007.
69. Wolf, S. F., Temple, P. A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., Hewick, R. M. (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146, 3074-3081.
70. Pflanz, S., Timans, J. C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibbert, L., Churakova, T., Travis, M., Vaisberg, E., Blumenschein, W. M., Mattson, J. D., Wagner, J. L., To, W., Zurawski, S., McClanahan, T. K, Gorman, D. M., Bazan, J. F., de Waal Malefyt, R., Rennick, D., Kastelein, R. A. (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16, 779-790.
71. Hisada, M., Kamiya, S., Fujita, K, Belladonna, M. L., Aoki, T., Koyanagi, Y., Mizuguchi, J., Yoshimoto, T. (2004) Potent antitumor activity of interleukin-27. Cancer Res. 64, 1152-1156.
72. Stumhofer, J.S., Silver, J.S., Laurence, A., Porrett, P.M., Harris, T.H., Turka, L.A., Ernst, M., Saris, C.J., O'Shea, J.J., Hunter, C.A. (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8, 1363-1371.
73. Xu, M., Mizoguchi, I., Morishima, N., Chiba, Y., Mizuguchi, J., Yo-shimoto, T. (2010) Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin. Dev. Immunol. 2010, 832454.
74. Chen, Q., Ghilardi, N., Wang, H., Baker, T., Xie, M. H., Gurney, A., Grewal, I. S., de Sauvage, F. J. (2000) Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407, 916-920.
75. Yoshimoto, T., Yoshimoto, T., Yasuda, K., Mizuguchi, J., Nakanishi, K (2007) IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-medi-ated allergic inflammation. J. Immunol. 179, 4415-4423.
76. Fitzgerald, D. C., Zhang, G. X., El-Behi, M., Fonseca-Kelly, Z., Li, H., Yu, S., Saris, C. J., Gran, B., Ciric, B., Rostami, A. (2007) Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8, 13721379.
77. Pistoia, V., Cocco, C., Airoldi, I. (2009) Interleukin-12 receptor β2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J. Clin. Oncol. 27, 4809-4816.
78. Airoldi, I., Cocco, C., Di Carlo, E., Disaro, S., Ognio, E., Basso, G., Pistoia, V. (2006) Methylation of the IL-12Rβ2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res. 66, 3978-3980.
79. Airoldi, I., Cocco, C., Giuliani, N., Ferrarini, M., Colla, S., Ognio, E., Taverniti, G., Di Carlo, E., Cutrona, G., Perfetti, V., Rizzoli, V., Ribatti, D., Pistoia, V. (2008) Constitutive expression of IL-12R β 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 112, 750-759.
80. Ferretti, E., Di Carlo, E., Cocco, C., Ribatti, D., Sorrentino, C., Ognio, E., Montagna, D., Pistoia, V., Airoldi, I. (2010) Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol. Lett. 133, 99-105.
81. Akashi, K., Harada, M., Shibuya, T., Eto, T., Takamatsu, Y., Teshima, T., Niho, Y. (1991) Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34-blasts from acute myelogenous leukemia. Blood 78, 197-204.
82. Shimizu, M., Shimamura, M., Owaki, T., Asakawa, M., Fujita, K, Kudo, M., Iwakura, Y., Takeda, Y., Luster, A. D., Mizuguchi, J., Yoshimoto, T. (2006) Antiangiogenic and antitumor activities of IL-27. J. Immunol. 176, 7317-7324.
83. Canale, S., Cocco, C., Frasson, C., Seganfreddo, E., Di Carlo, E., Ognio, E., Sorrentino, C., Ribatti, D., Zorzoli, A., Basso, G., Dufour, C., Airoldi, I. (2011) Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 25, 1815-1824.
84. Cocco, C., Di Carlo, E., Zupo, S., Canale, S., Zorzoli, A., Ribatti, D., Mo-randi, F., Ognio, E., Airoldi, I. (2011) Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia, Epub ahead of print.
85. Cocco, C., Giuliani, N., Di Carlo, E., Ognio, E., Storti, P., Abeltino, M., Sorrentino, C., Ponzoni, M., Ribatti, D., Airoldi, I. (2010) Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin. Cancer Res. 16, 4188-4197.
86. Yoshimoto, T., Morishima, N., Mizoguchi, I., Shimizu, M., Nagai, H., Oniki, S., Oka, M., Nishigori, C., Mizuguchi, J. (2008) Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180, 6527-6535.
87. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., Sherman, M. L. (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409-417.
88. Gollob, J. A., Veenstra, K G., Parker, R. A., Mier, J. W., McDermott, D. F., Clancy, D., Tutin, L., Koon, H., Atkins, M. B. (2003) Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 21, 2564-2573.
89. Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N.J., Ryan, J. L. (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-7 production. Blood 90, 25412548.
90. Portielje, J. E., Gratama, J. W., van Ojik, H. H., Stoter, G., Kruit, W. H. (2003) IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 52, 133-144.
91. Heinzerling, L., Burg, G., Dummer, R., Maier, T., Oberholzer, P. A., Schultz, J., Elzaouk, L., Pavlovic, J., Moelling, K (2005) Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum. Gene Ther. 16, 35-48.
92. Heinzerling, L., Dummer, R., Pavlovic, J., Schultz, J., Burg, G., Moelling, K. (2002) Tumor regression of human and murine melanoma after in-tratumoral injection of IL-12-encoding plasmid DNA in mice. Exp. Dermatol. 11, 232-240.
93. Kang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S. S., Lee, M. H., Park, K, Kim, K, Jeong, H. S., Kim, J. A., Nam, S. J., Yang, J. H., Son, Y. I., Baek, C. H., Han, J., Ree, H.J., Lee, E. S., Kim, S. H., Kim, D. W., Ahn, Y. C., Huh, S. J., Choe, Y. H., Lee, J. H., Park, M. H., Kong, G. S., Park, E. Y., Kang, Y. K., Bang, Y. J., Paik, N. S., Lee, S. N., Kim, S. H., Kim, S., Robbins, P. D., Tahara, H., Lotze, M. T., Park, C. H. (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 12, 671-684.
94. Sun, Y., Jurgovsky, K, Moller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B., Schadendorf, D. (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther. 5, 481-490.
95. Gafner, V., Trachsel, E., Neri, D. (2006) An engineered antibody-inter-leukin-12 fusion protein with enhanced tumor vascular targeting properties. Int. J. Cancer 119, 2205-2212.
96. Halin, C., Gafner, V., Villani, M. E., Borsi, L., Berndt, A., Kosmehl, H., Zardi, L., Neri, D. (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor a. Cancer Res. 63, 3202-3210.
97. Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K E., Messina, J. L., Heller, R. (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26, 5896-5903.
98. Oniki, S., Nagai, H., Horikawa, T., Furukawa, J., Belladonna, M. L., Yoshimoto, T., Hara, I., Nishigori, C. (2006) Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66, 6395-6404.
99. Seita, J., Asakawa, M., Ooehara, J., Takayanagi, S., Morita, Y., Watanabe, N., Fujita, K, Kudo, M., Mizuguchi, J., Ema, H., Nakauchi, H., Yo-shimoto, T. (2008) Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 111, 1903-1912.